Some consumers have developed out-of-character thoughts of suicide & self-harm after taking the weight loss drugs, Wegovy and Ozempick, two products sold by Novo Nordisk.

“Suicidal behaviour is not currently listed as a side effect in the EU product information of these medicines,” the EMA said. “The PRAC will consider whether the review should be extended to also include other medicines of the same class (‘GLP-1 receptor agonist’).” Read the full article at https://www.cnbc.com/2023/07/10/european-regulator-to-review-drugs-after-reports-of-suicidal-thoughts.html.